X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs CIPLA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH CIPLA STERLING BIOTECH/
CIPLA
 
P/E (TTM) x -1.8 45.7 - View Chart
P/BV x 0.1 3.9 1.7% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 STERLING BIOTECH   CIPLA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
CIPLA
Mar-17
STERLING BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs11622 1.7%   
Low Rs3458 0.7%   
Sales per share (Unadj.) Rs26.8181.9 14.7%  
Earnings per share (Unadj.) Rs-15.012.9 -116.2%  
Cash flow per share (Unadj.) Rs-5.529.3 -18.6%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs54.9155.7 35.3%  
Shares outstanding (eoy) m267.87804.51 33.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 8.7%   
Avg P/E ratio x-0.542.0 -1.1%  
P/CF ratio (eoy) x-1.318.4 -6.9%  
Price / Book Value ratio x0.13.5 3.7%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m1,862434,516 0.4%   
No. of employees `0001.423.0 5.9%   
Total wages/salary Rs m54726,338 2.1%   
Avg. sales/employee Rs Th5,303.36,349.1 83.5%   
Avg. wages/employee Rs Th403.81,143.0 35.3%   
Avg. net profit/employee Rs Th-2,959.0449.3 -658.5%   
INCOME DATA
Net Sales Rs m7,181146,302 4.9%  
Other income Rs m432,287 1.9%   
Total revenues Rs m7,223148,589 4.9%   
Gross profit Rs m94724,758 3.8%  
Depreciation Rs m2,54313,229 19.2%   
Interest Rs m4,3771,594 274.6%   
Profit before tax Rs m-5,93112,222 -48.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,798 -107.0%   
Profit after tax Rs m-4,00710,354 -38.7%  
Gross profit margin %13.216.9 77.9%  
Effective tax rate %32.414.7 220.6%   
Net profit margin %-55.87.1 -788.4%  
BALANCE SHEET DATA
Current assets Rs m14,33587,370 16.4%   
Current liabilities Rs m49,80933,081 150.6%   
Net working cap to sales %-494.037.1 -1,331.3%  
Current ratio x0.32.6 10.9%  
Inventory Days Days40387 463.9%  
Debtors Days Days17162 273.9%  
Net fixed assets Rs m55,432111,567 49.7%   
Share capital Rs m2681,609 16.7%   
"Free" reserves Rs m13,935123,645 11.3%   
Net worth Rs m14,701125,254 11.7%   
Long term debt Rs m9,47836,454 26.0%   
Total assets Rs m73,988209,532 35.3%  
Interest coverage x-0.48.7 -4.1%   
Debt to equity ratio x0.60.3 221.5%  
Sales to assets ratio x0.10.7 13.9%   
Return on assets %0.55.7 8.8%  
Return on equity %-27.38.3 -329.7%  
Return on capital %-6.48.5 -75.6%  
Exports to sales %25.934.2 75.7%   
Imports to sales %0.28.3 2.0%   
Exports (fob) Rs m1,86050,050 3.7%   
Imports (cif) Rs m1212,203 0.1%   
Fx inflow Rs m1,86051,066 3.6%   
Fx outflow Rs m2517,678 0.1%   
Net fx Rs m1,83533,388 5.5%   
CASH FLOW
From Operations Rs m1,71923,824 7.2%  
From Investments Rs m-3,148-13,127 24.0%  
From Financial Activity Rs m1,426-13,239 -10.8%  
Net Cashflow Rs m-3-2,478 0.1%  

Share Holding

Indian Promoters % 33.9 16.0 211.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 9.9 23.7 41.8%  
ADR/GDR % 16.9 1.1 1,536.4%  
Free float % 39.3 26.2 150.0%  
Shareholders   21,482 161,166 13.3%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  FULFORD INDIA  MERCK LTD  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Feb 16, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS